Long-term serum levels of residual platinum correlate with the severity of neurotoxicity five to 20 years after chemotherapy in testicular cancer (TC) survivors, even after adjusting for initial cisplatin dose, according to a study published online Dec. 19 in the Journal of Clinical Oncology.
Medivation and Astellas announced positive results from an interim analysis of the Phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer previously treated with chemotherapy.
Amgen announced that the FDA has approved Prolia (denosumab injection) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.
Abbott announced that the FDA has approved a 45mg for six-month administration formulation of Lupron Depot (leuprolide acetate for depot suspension) for the palliative treatment of advanced prostate cancer.
Centocor Ortho Biotech announced that the FDA has approved Zytiga (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.
